Skip to Main Content

Paper Details

Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities.
Anticancer Agents Med Chem
18
2013

Datasets